Amos A. Fatokun is the Professor of
Pharmacology and Neuroscience within the School of Pharmacy and Biomolecular
Sciences and the Pharmacology Section Lead as well as Communications Lead for
Liverpool John Moores University’s Centre for Natural Products Discovery
(CNPD). He trained as a pharmacist at the Obafemi Awolowo University, Nigeria,
graduating with a BPharm. Before that, he studied between 2003 and 2006 for a
Ph.D. in Pharmacology and Neuroscience at the University of Glasgow, UK. He
holds a Postgraduate Certificate in Higher Education Practice (PGCHEP) and is a
Fellow of the UK Higher Education Academy (FHEA). Professor Amos A. Fatokun’s
research focuses on elucidating the cellular and molecular mechanisms
underlying disease conditions characterized by either excessive cell death,
e.g., neurodegenerative diseases (such as Parkinson’s Disease and Alzheimer's
Disease), or impaired cell death (such as cancers), to harness the knowledge to
develop novel therapeutics that will be more efficacious and elicit fewer side
effects in managing those conditions.
Amos A. Fatokun is the Professor of
Pharmacology and Neuroscience within the School of Pharmacy and Biomolecular
Sciences and the Pharmacology Section Lead as well as Communications Lead for
Liverpool John Moores University’s Centre for Natural Products Discovery
(CNPD). He trained as a pharmacist at the Obafemi Awolowo University, Nigeria,
graduating with a BPharm. Before that, he studied between 2003 and 2006 for a
Ph.D. in Pharmacology and Neuroscience at the University of Glasgow, UK. He
holds a Postgraduate Certificate in Higher Education Practice (PGCHEP) and is a
Fellow of the UK Higher Education Academy (FHEA). Professor Amos A. Fatokun’s
research focuses on elucidating the cellular and molecular mechanisms
underlying disease conditions characterized by either excessive cell death,
e.g., neurodegenerative diseases (such as Parkinson’s Disease and Alzheimer's
Disease), or impaired cell death (such as cancers), to harness the knowledge to
develop novel therapeutics that will be more efficacious and elicit fewer side
effects in managing those conditions.